CN111568997A - Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof - Google Patents

Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof Download PDF

Info

Publication number
CN111568997A
CN111568997A CN202010569383.XA CN202010569383A CN111568997A CN 111568997 A CN111568997 A CN 111568997A CN 202010569383 A CN202010569383 A CN 202010569383A CN 111568997 A CN111568997 A CN 111568997A
Authority
CN
China
Prior art keywords
parts
fatty liver
traditional chinese
chinese medicine
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010569383.XA
Other languages
Chinese (zh)
Inventor
朱俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huaining Huachun Hepatopathy Hospital
Original Assignee
Huaining Huachun Hepatopathy Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huaining Huachun Hepatopathy Hospital filed Critical Huaining Huachun Hepatopathy Hospital
Priority to CN202010569383.XA priority Critical patent/CN111568997A/en
Publication of CN111568997A publication Critical patent/CN111568997A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/884—Alismataceae (Water-plantain family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968—Ophiopogon (Lilyturf)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention provides a traditional Chinese medicine composition for treating obesity type fatty liver and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for treating the obesity type fatty liver comprises the following substances: lotus leaf, cortex moutan, herba patriniae, folium sennae, radix ophiopogonis, polygonum multiflorum, raw hawthorn, salvia miltiorrhiza, schisandra chinensis, rhizoma alismatis, dark plum and red paeony root. The invention overcomes the defects of the prior art, provides the traditional Chinese medicine composition for specially treating the obese fatty liver, and has the advantages of good curative effect, small side effect, simple treatment process and the like.

Description

Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof
Technical Field
The invention relates to a traditional Chinese medicine composition and a preparation method thereof, in particular to a traditional Chinese medicine composition for treating obesity type fatty liver and a preparation method thereof.
Background
Fatty liver refers to the condition that fat is accumulated in the liver too much, and the accumulation exceeds more than 5% of the content of fatty liver, and the pathogenesis of fatty liver is generally caused by the following reasons: 1. fatty liver of obesity: the degree of fat accumulation in the liver is in direct proportion to the body weight, 30 to 50 percent of obesity is combined with fatty liver, and the fatty liver variability of severely obese people is up to 61 to 94 percent; 2. alcoholic fatty liver: when the liver of a person who is drunk for a long time is subjected to puncture biopsy, 75% -95% of the liver is infiltrated with fat, and the incidence rate of alcoholic fatty liver is increased by 5-25 times when the person who is drunk for a day exceeds 80-160 g; 3. fast weight loss fatty liver: fasting, overeating, or other rapid weight loss measures can cause a large increase in lipolysis in the short term, depletion of intrahepatic Glutathione (GSH), large increases in intrahepatic malondialdehyde and lipid peroxides, damage to hepatocytes, and lead to fatty liver; 4. dystrophic fatty liver: protein deficiency caused by malnutrition is an important reason for causing fatty liver, and is often caused by insufficient ingestion or digestion disorder, and apolipoprotein cannot be synthesized, so that triglyceride is accumulated in the liver to form fatty liver; 5. diabetic fatty liver: fatty liver occurs in about 50% of diabetics, with adults being more, because 50-80% of diabetics after adulthood are obese, their plasma insulin levels are increased by plasma fatty acids, and fatty liver changes are associated with both obesity and eating fat or excessive sugar; 6. drug-induced fatty liver: certain drugs or chemical poisons cause fatty liver by inhibiting protein synthesis, such as tetracycline, adrenocortical hormone, puromycin, cyclohexylamine, emetine, as well as arsenic, lead, silver, mercury, and the like. Lipid lowering drugs can also form fatty liver by interfering with lipoprotein metabolism; 7. fatty liver in pregnancy: the disease is mostly developed in 34-40 weeks of first pregnancy, the disease condition is serious, the prognosis is poor, and the maternal and infant mortality reaches 80% and 70% respectively; 8. fatty liver caused by other diseases: fatty liver can also occur when tuberculosis, bacterial pneumonia, septicemia and other infections occur, and when activities of patients with viral hepatitis are excessively restricted and high-sugar and high-calorie diet is taken, liver cell fat is easy to accumulate; fatty liver is more likely to occur after treatment with corticosteroids. After controlling infection or removing the cause, fatty liver is rapidly improved, and there are high nutrition fatty liver in stomach and intestine, toxic fatty liver, fatty liver caused by hereditary disease, etc.
At present, a complete method for clinically treating fatty liver does not exist, western medicine is usually treated by adopting pure lipid-lowering medicines, the pathology of the fatty liver is not only the lipid-lowering problem, but also the damage to the liver function after intrahepatic fat infiltration is included, and the pure lipid-lowering medicines can generate side effects and damage the liver function. In contrast, the traditional Chinese medicine is relatively mild in treatment of the fatty liver, but the existing traditional Chinese medicine composition does not perform targeted treatment on the cause of the fatty liver when treating the fatty liver, has a gap in effect in the process of treating the fatty liver, does not have specific treatment standards, and is not convenient to popularize and use.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides the traditional Chinese medicine composition for treating the obese fatty liver and the preparation method thereof, and the traditional Chinese medicine composition is specially used for treating the obese fatty liver and has the advantages of good curative effect, small side effect, simple treatment process and the like.
In order to achieve the above purpose, the technical scheme of the invention is realized by the following technical scheme:
the traditional Chinese medicine composition for treating the obese fatty liver comprises the following substances in parts by weight: 23-28 parts of lotus leaf, 16-20 parts of cortex moutan, 16-20 parts of herba patriniae, 8-10 parts of folium sennae, 16-20 parts of radix ophiopogonis, 9-11 parts of polygonum multiflorum, 18-22 parts of raw hawthorn, 14-16 parts of salvia miltiorrhiza, 19-21 parts of schisandra chinensis, 14-16 parts of rhizoma alismatis, 14-16 parts of dark plum and 14-16 parts of red paeony root.
Preferably, the traditional Chinese medicine composition for treating the obese fatty liver comprises the following substances in parts by weight: 25 parts of lotus leaf, 18 parts of cortex moutan, 18 parts of herba patriniae, 9 parts of folium sennae, 18 parts of radix ophiopogonis, 10 parts of polygonum multiflorum, 20 parts of raw hawthorn, 15 parts of salvia miltiorrhiza, 20 parts of schisandra chinensis, 15 parts of rhizoma alismatis, 15 parts of dark plum and 15 parts of red paeony root.
The preparation method of the traditional Chinese medicine composition for treating the obesity type fatty liver comprises the following steps: mixing all the raw materials, putting into a casserole, adding water for immersion, boiling with strong fire, decocting with slow fire for 10min, filtering, adding water for immersion of the filter residue, repeating the above boiling process, and mixing the filtrates to obtain the final product.
Preferably, the traditional Chinese medicine composition is used by taking one dose every day, and 21 days are a treatment course.
The invention provides a traditional Chinese medicine composition for treating obesity type fatty liver and a preparation method thereof, and compared with the prior art, the traditional Chinese medicine composition has the advantages that:
the invention adopts the traditional Chinese medicine principle of adjusting viscera unbalance by adopting traditional Chinese medicines of strengthening body resistance and eliminating evil, softening hardness and dissipating stagnation, adopts a plurality of traditional Chinese medicines to mix and decoct, prepares the medicament, can effectively relieve and treat symptoms of fat fatty liver such as hepatomegaly, pain or discomfort of liver region, anorexia, abdominal fullness and distention, loose stool and the like, and has simple treatment method, good effect and no side effect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention are clearly and completely described below in conjunction with the embodiments of the present invention, and it is obvious that the described embodiments are some embodiments of the present invention, but not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
the traditional Chinese medicine composition for treating the obese fatty liver comprises the following substances in parts by weight: 23 parts of lotus leaf, 16 parts of cortex moutan, 16 parts of herba patriniae, 8 parts of folium sennae, 16 parts of radix ophiopogonis, 9 parts of polygonum multiflorum, 18 parts of raw hawthorn, 14 parts of salvia miltiorrhiza, 19 parts of schisandra chinensis, 14 parts of rhizoma alismatis, 14 parts of dark plum and 14 parts of red paeony root.
The preparation method comprises the following steps: mixing all the raw materials, putting into a casserole, adding water for immersion, boiling with strong fire, decocting with slow fire for 10min, filtering, adding water for immersion of the filter residue, repeating the above boiling process, and mixing the filtrates to obtain the final product.
Example 2:
the traditional Chinese medicine composition for treating the obese fatty liver comprises the following substances in parts by weight: 28 parts of lotus leaf, 20 parts of cortex moutan, 20 parts of herba patriniae, 10 parts of folium sennae, 20 parts of radix ophiopogonis, 11 parts of polygonum multiflorum, 22 parts of raw hawthorn, 16 parts of salvia miltiorrhiza, 21 parts of schisandra chinensis, 16 parts of rhizoma alismatis, 16 parts of dark plum and 16 parts of red paeony root.
The preparation method comprises the following steps: mixing all the raw materials, putting into a casserole, adding water for immersion, boiling with strong fire, decocting with slow fire for 10min, filtering, adding water for immersion of the filter residue, repeating the above boiling process, and mixing the filtrates to obtain the final product.
Example 3:
the traditional Chinese medicine composition for treating the obese fatty liver comprises the following substances in parts by weight: 25 parts of lotus leaf, 18 parts of cortex moutan, 18 parts of herba patriniae, 9 parts of folium sennae, 18 parts of radix ophiopogonis, 10 parts of polygonum multiflorum, 20 parts of raw hawthorn, 15 parts of salvia miltiorrhiza, 20 parts of schisandra chinensis, 15 parts of rhizoma alismatis, 15 parts of dark plum and 15 parts of red paeony root.
The preparation method comprises the following steps: mixing all the raw materials, putting into a casserole, adding water for immersion, boiling with strong fire, decocting with slow fire for 10min, filtering, adding water for immersion of the filter residue, repeating the above boiling process, and mixing the filtrates to obtain the final product.
Example 4:
173 clinical patients (Huaichun hospital in Huaningcounty) in the hospital are selected, and are all patients with fatty liver with liver dysfunction (alcoholic fatty liver is excluded in all cases), the 173 patients are randomly divided into two groups, namely a treatment group and a control group, wherein the treatment group adopts 1 dose of the medicament prepared in the example 3 every day, and the control group adopts 0.1g of fenofibrate at a time, 3 times every day, 250mg of sodium ursodesoxycholic acid at a time, 2 times every day, and 3 times every day of vitamin C0.2mg; in the two groups of treatments, the treatment course is 1 treatment course after 3 weeks, the interval is 1 week, the B ultrasonic and liver functions are rechecked, the treatment effect is evaluated after 3 treatment courses by taking 7 days as 1 detection period, and the results (the patient symptoms are obviously relieved and are effective) are shown in the following table:
detection of Treatment group Control group
High efficiency 92.6％ 59.1％
Through statistical treatment, the two groups have significant difference (P is less than 0.01), the effect of the formula for treating the obese fatty liver is satisfactory, and clinically, patients taking the medicament in example 3 have obvious abdominal circumference reduction, and the weight is reduced by 4.2kg compared with the average value before taking the medicament.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus. Without further limitation, an element defined by the phrase "comprising an … …" does not exclude the presence of other identical elements in a process, method, article, or apparatus that comprises the element.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.

Claims (4)

1. The traditional Chinese medicine composition for treating the obese fatty liver is characterized by consisting of the following substances in parts by weight: 23-28 parts of lotus leaf, 16-20 parts of cortex moutan, 16-20 parts of herba patriniae, 8-10 parts of folium sennae, 16-20 parts of radix ophiopogonis, 9-11 parts of polygonum multiflorum, 18-22 parts of raw hawthorn, 14-16 parts of salvia miltiorrhiza, 19-21 parts of schisandra chinensis, 14-16 parts of rhizoma alismatis, 14-16 parts of dark plum and 14-16 parts of red paeony root.
2. The traditional Chinese medicine composition for treating obese fatty liver as claimed in claim 1, wherein the traditional Chinese medicine composition for treating obese fatty liver comprises the following substances in parts by weight: 25 parts of lotus leaf, 18 parts of cortex moutan, 18 parts of herba patriniae, 9 parts of folium sennae, 18 parts of radix ophiopogonis, 10 parts of polygonum multiflorum, 20 parts of raw hawthorn, 15 parts of salvia miltiorrhiza, 20 parts of schisandra chinensis, 15 parts of rhizoma alismatis, 15 parts of dark plum and 15 parts of red paeony root.
3. A preparation method of a traditional Chinese medicine composition for treating obesity type fatty liver is characterized by comprising the following steps: the preparation method of the traditional Chinese medicine composition for treating the obesity type fatty liver comprises the following steps: mixing all the raw materials, putting into a casserole, adding water for immersion, boiling with strong fire, decocting with slow fire for 10min, filtering, adding water for immersion of the filter residue, repeating the above boiling process, and mixing the filtrates to obtain the final product.
4. The traditional Chinese medicine composition for treating the obese fatty liver according to claims 1 to 2, wherein the composition comprises the following components in percentage by weight: the traditional Chinese medicine composition is used by taking one dose every day, and 21 days are a treatment course.
CN202010569383.XA 2020-06-20 2020-06-20 Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof Pending CN111568997A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010569383.XA CN111568997A (en) 2020-06-20 2020-06-20 Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010569383.XA CN111568997A (en) 2020-06-20 2020-06-20 Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof

Publications (1)

Publication Number Publication Date
CN111568997A true CN111568997A (en) 2020-08-25

Family

ID=72118517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010569383.XA Pending CN111568997A (en) 2020-06-20 2020-06-20 Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111568997A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113274453A (en) * 2021-07-02 2021-08-20 河南省中医药研究院 Traditional Chinese medicine composition containing radix achyranthis bidentatae as menses guiding drug for treating yin deficiency and excessive heat type non-alcoholic fatty liver disease and preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张建平: "清热化湿法为主治疗脂肪肝63例", 《实用中医药杂志》 *
隋继成等: "肝脂消胶囊治疗肝炎合并脂肪肝52例", 《光明中医》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113274453A (en) * 2021-07-02 2021-08-20 河南省中医药研究院 Traditional Chinese medicine composition containing radix achyranthis bidentatae as menses guiding drug for treating yin deficiency and excessive heat type non-alcoholic fatty liver disease and preparation method and application thereof

Similar Documents

Publication Publication Date Title
CN101850047B (en) Chinese medicinal composition for treating eczema and preparation thereof
CN102895320A (en) Medicinal food formula and medicinal edible preparation for preventing and treating hyperuricemia and gout
CN101940743B (en) Chinese medicament for treating gastrosis and preparation method thereof
CN114712440A (en) Dai medicine composition for relieving senile cutaneous pruritus and preparation and application thereof
CN111568997A (en) Traditional Chinese medicine composition for treating obesity type fatty liver and preparation method thereof
CN111632110B (en) Traditional Chinese medicine enema composition for treating ulcerative colitis and preparation method and application thereof
CN112618560A (en) Pharmaceutical composition containing ginsenoside and application thereof in reducing blood fat and inhibiting fatty liver
CN101954060A (en) Medicament for treating stomach disease
CN105343423B (en) A kind of drug and preparation method thereof for treating eczema
CN104857107A (en) Fat-reducing composition preparation method and fat-reducing agent
CN104888062A (en) Drug for treating liver Yang hyperactivity type hypertensive disease and preparation method therefor
CN1772239A (en) Chinese medicine prepn for treating vaginitis and cervicitis
CN104547125A (en) Gastrointestinal drug and application thereof
CN102406790A (en) Traditional Chinese medicine capsule for treating hyperplasia of mammary glands and preparation method thereof
CN104771687B (en) The bilingual oral liquid of nine tastes is as the application for preparing treatment chronic hepatitis medicine
CN115944700B (en) Traditional Chinese medicine composition and preparation method and application thereof
CN112089783B (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity
CN106620318B (en) Traditional Chinese medicine composition for treating chronic nephritis
CN104721595A (en) Traditional Chinese medicine composition for treating hyperlipidaemia
CN112168931A (en) A pharmaceutical composition for treating oral ulcer, and its preparation method
CN112316102A (en) Traditional Chinese medicine composition for preventing or treating colitis
Yan et al. Phytochemistry, pharmacology, and clinical applications of Centella asiatica (L.) Urban
CN114632127A (en) Traditional Chinese medicine composition and preparation for treating pediatric jaundice as well as preparation method and application of traditional Chinese medicine composition and preparation
CN116196385A (en) Traditional Chinese medicine composition for treating fatty liver and/or liver fibrosis as well as preparation method and application thereof
CN117562942A (en) Traditional Chinese medicine composition for treating pulmonary nodules and thyroid nodules and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200825